Hyperresponsiveness in the human nasal airway: New targets for the treatment of allergic airway disease

Mediators of Inflammation

Volumn 8, Issue 3, 1999, Pages 133-146

  Turner, P J ^a   Foreman, J C ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Bradykinin; Eosinophils; Human nasal airway; Hyperresponsiveness; Neuropeptides; Nitric oxide

Indexed keywords

BRADYKININ; FREE RADICAL; LEUKOTRIENE; NEUROPEPTIDE; NITRIC OXIDE; PROSTAGLANDIN; THROMBOCYTE ACTIVATING FACTOR; THROMBOXANE;

ALLERGIC RHINITIS; BRONCHUS HYPERREACTIVITY; EOSINOPHIL; HUMAN; MEDIATOR RELEASE; NOSE AIRWAY RESISTANCE; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; UNITED KINGDOM;

ANIMALS; ANTIGENS; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; NASAL MUCOSA; RESPIRATORY HYPERSENSITIVITY; RHINITIS, ALLERGIC, PERENNIAL; RHINITIS, ALLERGIC, SEASONAL;

ANIMALIA; BRONCHUS;

EID: 0032809456     PISSN: 09629351     EISSN: None     Source Type: Journal    
DOI: 10.1080/09629359990469     Document Type: Review

References (165)

1. 1. British Society for Allergy and Clinical Immunology ENT Sub-committee: Guidelines on the management of rhinitis. London, 1994.
2. 2. Pretolani M, Vargaftig BB. From lung hypersensitivity to bronchial hyperreactivity - what can we learn from studies on animal models? Biochem Pharmacol 1993; 45: 791-800.
3. 3. Persson CGA, Erjefalt JS, Korsgren M, Sundler E The mouse trap. Trends Pharmacol Sci 1997; 18: 465-467.
4. 4. Naclerio RM, Meier HL, Kagey-Sobotka A et al. Mediator release after nasal airway challenge with allergen. Am Rev Respir Dis 1983; 128: 597-602.
5. 5. Dear JW. The bradykinin receptor in the human nasal airway: its characteristics and role in allergic rhinitis. University of London (PhD Thesis), 1996.
6. 6. Maruo K, Akaike T, Matsumura Y et al. Triggering of the vascular permeability reaction by activation of the Hageman factor-prekallikrein system by house dust mite proteinase Biochim Biophys Acta 1991; 1074: 62-68.
7. 7. Stewart GA, Thompson PJ, McWilliam AS. Biochemical properties of aeroallergens: contributory factors in allergic sensitisation? Pediatr Allergy Immunol 1993; 4: 163-172.
8. 8. Druce HW, Wright RH, Kossol D, Kaliner MA. Cholinergic nasal hyperreactivity in atopic subjects J Allergy Clin Immunol 1985; 76: 445-452.
9. 9. Mullins RJ, Olson LG, Sutherland DC. Nasal histamine challenges in symptomatic allergic rhinitis. J Allergy Clin Immunol 1989; 83: 955-959.
10. 10. Van Wijk RG, Zijlstra FJ, Van Toorenenbergen AW, Vermeulen A, Dieges PH. Isolated early response after nasal allergen challenge is sufficient to induce nasal hyperreactivity. Ann Allergy 1992; 69: 43-47.
11. 11. Aizawa H, Miyazaki N, Shigematsu N, Tomooka M. A possible role of airway epithelium in modulating hyperresponsiveness. Br J Pharmacol 1988; 93: 139-145.
12. 12. Laitinen LA, Heino M, Laitinen A, Kava T, Haahtela T. Damage of the airway epithelium and bronchial reactivity in patients with asthma. Am Rev Respir Dis 1985; 131: 599-606.
13. 13. Ohashi Y, Nakai Y, Morimoto K et al. Platelet activating factor compromises airway epithelial defense functions. J Allergy Clin Immunol 1997; 100: 520-526.
14. 14. Hulsmann AR, Raatgeep HR, den Hollander JC et al. Oxidative epithelial damage produces hyperresponsiveness of human peripheral airways. Am J Respir Crit Care Med 1994; 149: 519-525.
15. 15. Riccio MM, Proud D. Evidence that enhanced nasal reactivity to bradykinin in patients with symptomatic allergy is mediated by neural reflexes. J Allergy Clin Immunol 1996; 97: 1252-1263.
16. 16. Svensson C, Andersson M, Greiff L, Persson CG. Nasal mucosal endorgan hyperresponsiveness. Am J Rhinol 1998; 12: 37-43.
17. 17. Holroyde MC. The influence of epithelium on the responsiveness of guinea-pig isolated trachea. Br J Pharmacol 1986; 87: 501-507.
18. 18. Devillier P, Advenier C, Drapeau G, Marsac J, Regoli D. Comparison of the effects of epithelium removal and of an enkephalinase inhibitor on the neurokinin-induced contractions of guinea-pig isolated trachea. Br J Pharmacol 1988; 94: 675-684.
19. 19. Sparrow MP, Omari TI, Mitchell HW. The epithelial barrier and airway responsiveness. Can J Physiol Pharmacol 1995; 73: 180-190.
20. 20. Advenier C, Devillier P, Matran R, Naline E. Influence of epithelium on the responsiveness of guinea-pig isolated trachea to adenosine. Br J Pharmacol 1988; 93: 295-302.
21. 21. Koga Y, Satoh S, Sodeyama N, Hashimoto Y, Yanagisawa T, Hirshman CA. Role of acetylcholinesterase in airway epithelium-mediated inhibition of acetylcholine induced contraction of guinea-pig isolated trachea. Eur J Pharmacol 1992; 220: 141-146.
22. 22. Butterfield JH, Leiferman KM. Eosinophil-associated disease. In: Smith H, Cook RM, eds Immunopharmacology of Eostnophils. London: Academic Press, 1993; 151-192.
23. 23. Coyle AJ, Ackerman SJ, Irvin CG. Cationic proteins induce airway hyperresponsiveness dependent on charge interactions. Am Rev Respir Dis 1993; 147: 896-900.
24. 24. White MV. Nasal cholinergic hyperresponsiveness in atopic subjects studied out of season. J Allergy Clin Immunol 1993, 92: 278-287.
25. 25. Van Megen YJB, Klaassen ABM, Rogrigues de Miranda JF, van Ginneken CAM, Wentges BTR. Alterations of muscarinic acetylcholine receptors in the nasal mucosa of allergic patients in comparison with nonallergic individuals. J Allergy Clin Immunol 1991; 87: 521-529.
26. 26. Van Megen YJB, Klaassen ABM, Rogrigues de Miranda JF, van Ginneken CAM, Wentges BTR. Alterations of adrenoceptors in the nasal mucosa of allergic patients in comparison with nonallergic individuals. J Allergy Clin Immunol 1991; 87: 530-540.
27. 27. Lacroix JS, Kurt AM, Pochon N, Bretton C, Lundberg JM, Deshusses J. Neutral endopeptidase activity and concentration of sensory neuropeptide in the human nasal mucosa. Eur Arch Otorhinolaryngol 1995; 252: 465-468.
28. 28. Elrod KC, Moore WR, Abraham WM, Tanaka RD. Lactoferrin, a potent tryptase inhibitor, abolishes late-phase airway responses in allergic sheep. Am J Respir Crit Care Med 1997; 156: 375-381.
29. 29. Molinari JF, Scuri M, Moore WR, Clarke J, Tanaka RD, Abraham WM. Inhaled tryptase causes bronchoconstriction in sheep via histamine release. Am J Respir Crit Care Med 1996; 154: 649-653.
30. 30. Johnson PR, Ammit AJ, Carlin SM, Armour CL, Caughey GH, Black JL. Mast cell tryptase potentiates histamine-induced contraction in human sensitized bronchus. Eur Respir J 1997; 10: 38-43.
31. 31. Teixeira MM, Gristwood RW, Cooper N, Hellewell PG. Phosphodiesterase (PDE)4 inhibitors: Anti-inflammatory drugs of the future? Trends Pharmacol Sci. 1997; 18: 164-170.
32. 32. Harbinson PL, MacLeod D, Hawksworth R et al.The effect of a novel orally active selective PDE4 isoenzyme inhibitor (CDP840) on allergen-induced responses in asthmatic subjects. Eur Respir J 1997; 10: 1008-1014.
33. 33. Sadeghi-Hashjin G, Folkerts G, Henricks PAJ et al. Peroxynitrite induces airway hyperresponsiveness in guinea pigs in vitro and in vivo. Am J Respir Crit Care Med 1996; 153: 1697-1701.
34. 34. Kips JC, Lefebvre RA, Peleman RA, Joos GF, Pauwels RA. The effect of a nitric oxide synthase inhibitor on the modulation of airway responsiveness in rats. Am J Respir Crit Care Med 1995; 151: 1165-1169.
35. 35. Bascom R, Pipkorn U, Proud D et al. Major basic protein and eosinophil-derived neurotoxin concentrations in nasal lavage fluid after antigen challenge effect of systemic corticosteroids and relationship to eosinophil influx. J Allergy Clin Immunol 1989; 84: 338-346.
36. 36. Svennson C, Andersson M, Persson CGA, Venge P, Alkner U, Pipkorn U. Albumin, bradykinin, and eosinophil cationic protein on the nasal mucosal surface in patients with hay fever during natural allergen exposure. J Allergy Clin Immunol 1990; 85: 828-833.
37. 37. Knani J, Campbell A, Enander I, Peterson CGB, Michel F-B, Bousquet J. Indirect evidence of nasal inflammation assessed by titration of inflammatory mediators and enumeration of cells in nasal secretions of patients with chronic rhinitis J Allergy Clin Immunol 1992; 90: 880-889.
38. 38. Kato M, Hattori T, Kitamura M, Beppu R, Yanagita N, Nakashima I. Major basic protein and topical administration of ketotifen in pollinosis under natural allergen provocation. ORI. 1995; 57: 269-272.
39. 39. Nishioka K, Ogawa T, Saito C et al. Major basic protein, eosinophil cationic protein, and arylsulfatase in nasal secretions of patients with Japanese cedar pollinosis. Acta Med Okayama 1995; 49: 29-33.
40. 40. Gleich GJ, Abu-Ghazalch RA, Glitz DG. Eosinophil granule proteins -structure and function. In: Gleich GJ, Kay AB, eds. Eosinophils in Allergy and Inflammation. New York: Marcel Dekker, 1994; 1-18.
41. 41. Shin MH, Averill FJ, Hubbard WC et al. Nasal allergen challenge generates I-O-hexadecyl-2-lyso-sn-glycero-3-phosphocholine. Am J Respir Crit Care Med 1994; 149: 660-666.
42. 42. Flavahan NA, Stifman NR, Gleich GJ, Vanhoutte PM. Human eosinophil major basic protein causes hyperreactivity of respiratory smooth muscle. Role of the epithelium. Am Rev Respir Dis 1988; 138: 685-688.
43. 43. Gleich GJ. The eosinophil and asthma. In: Morley J, Colditz I, eds. Eosinophils in Asthma. London: Academic Press, 1989; 259-266.
44. 44. Gundel RH, Letts LG, Gleich GJ. Human eosinophil major basic protein induces airway constriction and airway hyperresponsiveness in primates. J Clin Invest 1991; 87: 1470-1473.
45. 45. Coyle AJ, Perretti F, Manzini S, Irvin CG. Cationic protein-induced sensory nerve activation: role of substance P in airway hyperresponsiveness and plasma extravasation. J Clin Invest 1994; 94: 2301-2306.
46. 46. Coyle AJ, Ackerman SJ, Burch RM, Proud D, Irvin CG. Human eosinophil-granule major hasic protein and synthetic polycations induce airway hyperresponsiveness in vivo dependent on bradykinin generation. J Clin Invest 1995; 95: 1735-1740.
47. 47. Linder A, Venge P, Deuschl H Eosinophil cationic protein and myeloperoxidase in nasal secretions as markers of inflammation in allergic rhinitis. Allergy 1987; 42: 583-590.
48. 48. Andersson M, Andersson P, Venge P, Pipkorn U. Eosinophils and eosinophil cationic protein in nasal lavages in allergen-induced hyperresponsiveness: effects of topical glucocorticosteroid treatment. Allergy 1989; 44: 342-348.
49. 49. Klementsson H, Venge P, Andersson M, Pipkorn U. Allergen-induced changes in nasal secretory responsiveness and eosinophil granulocytes. Acta Otolaryngol. (Stockholm) 1991, 111: 776-784.
50. 50. Barnes PJ, Chung KF, Page CP. Platelet-activating factor as a mediator of allergic disease. J Allergy Clin Immunol 1988; 81: 919-934.
51. 51. Andersson M, Pipkorn U. The effect of platelet activating factor on nasal hypersensitivity. Eur J Clin Pharmacol 1988; 35: 231-235.
52. 52. Austin CE, Foreman JC. The effect of platelet activating factor on the responsiveness of the human nasal mucosa. Br J Pharmacol 1993; 110: 113-118.
53. 53. Tedeschi A, Milazzo N, Miadonna A. Nasal eosinophilia induced by PAF-acether is accompanied by the release of eosinophil cationic protein. Eur Respir J 1994; 7: 1445-1451.
54. 54. Tedeschi A, Palumbo G, Milazzo N, Miadonna. A nasal neutrophilia and eosinophilia induced by challenge with platelet activating factor. J Allergy Clin Immunol 1994; 93: 526-533.
55. 55. Miadonna A, Tedeschi A, Arnoux B, Sala A, Zanussi C, Benveniste J. Evidence of PAF-acether metabolic pathway activation in antigen challenge on upper respiratory airways. Am Rev Respir Dis 1989; 140: 142-147.
56. 56. Tsai JJ, Ho CY, Wang SR. Relationship between nasal resistance and airway hyperreactivity following nasal provocation with Dermatophagoides pteronyssinus in allergic rhinitis. Int Arch Allergy Immunol 1995; 106: 286-290.
57. 57. Touqui L, Herpin-Richard N, Gene RM et al. Excretion of platelet activating factor-acetylhydrolase and phospholipase A2 into nasal fluids after allergenic challenge: possible role in the regulation of platelet activating factor release. J Allergy Clin Immunol 1994; 94: 109-119.
58. 58. Hwang SB, Lam MH, Shen TY. Specific binding sites for platelet activating factor in the human lung. Biochem Biophys Res Comm 1985; 128: 972-979.
59. 59. Arima M, Manaka K, Fukuda T, Makino S. Role of platelet-activating factor in the release of neutrophil and eosinophil chemotactic attractants from cultured guinea-pig tracheal epithelial cells. Int Arch Allergy Immunol 1995; 108 (Suppl 1): 19-24.
60. 60. Soler M, Sielczak MW, Abraham WM. A PAF antagonist blocks antigen-induced airway hyperresponsiveness and inflammation in sheep. J Appl Physiol 1989; 67: 406-413.
61. 61. Coyle AJ, Page CP, Atkinson L, Sjoerdsma K, Touvay C, Metzger WJ. Modification of allergen-induced airway obstruction and airway hyperresponsiveness in an allergic rabbit model by the selective platelet-activating factor antagonist, BN 52024. J Allergy Clin Immunol 1989; 84: 960-967.
62. 62. Ishida K, Thomson RJ, Beattie LL, Wiggs B, Schellenberg RR. Inhibition of antigen-induced airway hyperresponsiveness, but not acute hypoxia nor airway eosinophilia, by an antagonist of platelet activating factory. J Immunol 1990; 144: 3907-3911.
63. 63. Kuitert LM, Hui KP, Uthayarkumar S et al. Effect of the platelet activating factor antagonist UK-74,505 on the early and late response to allergen. Am Rev Respir Dis 1993; 147: 82-86.
64. 64. Ganbo T, Hisamatsu K-I. Mucosal dysfunction and damage induced by platelet activating factor (PAF). Acta Otolaryngol (Stockholm) 1990; 110: 427-436.
65. 65. Webber SE, Morikawa T, Widdicombe JG. PAF-induced muscarinic cholinoceptor hyperresponsiveness of ferret tracheal smooth muscle and gland secretion in vitro. Br J Pharmacol 1992; 105: 230-237.
66. 66. Naclerio RM, Proud D, Togias A et al. Inflammatory mediators in late antigen-induced rhinitis. New Engl J Med 1985; 313: 65-70.
67. 67. De Graaf-in 't Veld C, Garrelds TM, Koenders S, Gerth van Wijk R. Relationship between nasal hyperreactivity, mediators and eosinophils in patients with perennial allergic rhinitis and controls. Clin Exp Allergy 1996; 26: 903-908.
68. 68. Wang CG, Du T, Xu LJ, Martin JG. Role of leukotriene D4 in allergen-induced increases in airway smooth muscle in rat. Am Rev Respir Dis 1993; 148: 413-417.
69. 4-induced histamine hyperresponsiveness in asthmatic subjects. Am Rev Respir Dis 1992; 146: 1506-1510.
70. 70. Knapp HR. Reduced allergen-induced nasal congestion and leukotriene synthesis with an orally active 5-lipoxygenase inhibitor. New Engl J Med 1990; 323: 1745-1748.
71. 71. Howarth PH. The cellular basis for allergic rhinitis. Allergy 1995; 50 (Suppl 23): 6-10.
72. 72. Fischer AR, McFadden CA, Frantz R et al. Effect of chronic 5-lipoxygenase inhibition on airway hyperresponsiveness in asthmatic subjects. Am J Respir Crit Care Med 1995; 152: 1207-1207.
73. 73. Obata T, Yamashita N, Nakagawa T. Leukotriene and thromboxane antagonists. Clin Rev Allergy 1994; 12: 79-93.
74. 74. Hamilton A, Faiferman I, Stober P, Watson RM, O'Byrne PM. Pranlukast, a cysteinyl leukotriene receptor antagonist, attenuates allergen-induced early-and late-phase bronchoconstriction and airway hyperresponsiveness in asthmatic subjects. J Allergy Clin Immunol 1998; 102: 177-183.
75. 4 antagonism is a primate model of asthma. J Clin Invest 1996; 97: 381-387.
76. 76. Seeds EA, Kilfeather S, Okiji S, Schoupe TS, Donihi-Gale D, Page CP. Role of lipoxygenase metabolites in platelet activating factor-and antigen-induced bronchial hyperresponsiveness and eosinophil infiltration. Eur J Pharmacol 1995; 293: 369-376.
77. 77. Weller PF. Lipid, peptide and cytokine mediators elaborated by eosinophils. In: Smith H, Cook RM, eds Immunopharmacology of Eosinophils. London: Academic Press, 1993; 25-42.
78. 78. Sugimoto M, Sugiyama S, Yanagita N, Ozawa T. Laser high performance liquid chromatography determination of prostaglandins in nasal lavage fluid in allergic rhinitis. Clin Exp Allergy 1994; 24: 324-329.
79. 2. Clin Exp Allergy 1996; 26: 371-378.
80. 80. Ramis I, Catafau JR, Serra J, Bulbena O, Picado C, Gelpi E. In vivo release of 15-HETE and other arachidonic acid metabolites in nasal secretions during early allergic reactions. Prostaglandins 1991; 42: 411-420.
81. 81. Folkerts G, Nijkamp FP. Airway epithelium: more than just a barrier! Trends Pharmacol Sci 1998, 19: 334-341.
82. 82. Chung KF, Aizawa H, Leikauf GD, Ueki IF, Evans TW, Nadel JA. Airway hyperresponsiveness induced by platelet activating factor: role of thromboxane generation. J Pharmacol Exp Ther 1986; 236: 580-584.
83. 83. Lanes S, Stevenson JS, Codias E et al. Indomethacin and FPL-57231 inhibit antigen-induced airway hyperresponsiveness in sheep. J Appl Physiol 1986; 61: 864-872.
84. 84. Jones GL, Saroea HG, Watson RM, O'Byrne PM. Effect of an inhaled thromboxane mimetic (U46619) on airway function in human subjects. Am Rev Respir Dis 1992; 145: 1270-1274.
85. 85. Itoh K, Takahashi E, Mukaiyama O, Satoh Y, Yamaguchi T. Effects of a thromboxane synthase inhibitor (CS-518) on the eosinophil-dependent late asthmatic response and airway hyperresponsiveness in guinea pigs. Int Arch Allergy Immunol 1996; 109: 79-84.
86. 86. Metwali A, Blum AM, Ferraris L, Klein JS, Fiocchi C, Weinstock JV. Eosinophils within the healthy or inflammed human intestine produce substance P and vasoactive intestinal peptide. J Neuroimmunology 1994; 52: 69-78.
87. 87. Mosimann BL, White MV, Hohman RJ, Goldrich MS, Kaulbach HC, Kaliner M. Substance P, calcitonin gene related peptide, and vasoactive intestinal peptide increase in nasal secretions after allergen challenge in atopic patients. J Allergy Clin Immunol 1993; 92: 95-104.
88. 88. Ladenius ARC, Biggs DF. Capsaicin prevents the induction of airway hyperresponsiveness in a guinea pig model of asthma. Am Rev Respir Dis 1989; 139: A232.
89. 89. Matsuse T, Thomson RJ, Chen XR, Salari H, Schellenberg RR. Capsaicin inhibits airway hyperresponsiveness but not lipoxygenase activity or eosinophilia after repeated aerolised antigen in guinea pigs. Am Rev Respir Dis 1991; 144: 368-372.
90. 90. Numao T, Agrawal DK. Neuropeptides modulate human eosinophil chemotaxis. J Immunol 1992; 149: 3309-3315.
91. 91. Van Oosterhout AJ, Van-Ark I, Hofman G, Van der Linde HJ, Fattah D, Nijkamp FP. Role of interleukin-5 and substance P in development of airway hyperrractivity to histamine in guinea-pigs. Eur Respir J 1996; 9: 493-499.
92. 92. Greiff L, Svensson C, Andersson M, Persson CG. Effects of topical capsaicin in seasonal allergic rhinitis Thorax 1995; 50: 225-229.
93. 93. Sanico AM, Atsuta S, Proud D, Togias A. Dose-dependent effects of capsaicin nasal challenge: in vivo evidence of human airway neurogenic inflammation. J Allergy Clin Immunol 1997; 100: 632-641.
94. 94. Philip G, Sanico AM, Togias A. Inflammatory cellular influx follows capsaicin nasal challenge. Am J Respir Crit Care Med 1996; 153: 1222-1229.
95. 95. Stjarne P, Rinder J, Heden-Blomquist E et al. Capsaicin desensitization of the nasal mucosa reduces symptoms upon allergen challenge in patients with allergic rhinitis. Acta Otolaryngol (Stockholm) 1998; 118: 235-239.
96. 96. Zhang R, Jiang D, Li Z. Clinical observation and therapeutic mechanism of blocking agent of substance P nerves in the treatment of perennial allergic rhinitis. Chung Hua Erb Pi Yen Hou Ko Tsa Chib 1995; 30: 163-165.
97. 97. Baumgarten CR, O'Connor A, Dokic D, Schultz KD, Kunkel G. Substance P is generated in vivo following nasal challenge of allergic individuals with bradykinin. Clin Exp Allergy 1997; 27: 1322-1327.
98. 98. Saria A, Martling CR, Yan Z, Theodorsson-Norheim E, Gamse R, Lundberg JM. Release of multiple tachykinins from capsaicin sensitive sensory nerves in the lung by bradykinin, histamine, dimethylphenyl piperazinium, and vagal nerve stimulation. Am Rev Respir Dis 1988; 137: 1330-1335.
99. 99. Okamoto Y, Shirotori K, Kudo K et al. Cytokine expression after the topical administration of substance P to human nasal mucosa. The role of substance P in nasal allergy. J Immunol 1993; 151: 4391-4398.
100. 100. Kohrogi H; Yamaguchi T, Kawano O, Honda I, Ando M, Araki S. Inhibition of neutral endopeptidase potentiates bronchial contraction induced by immune response in guinea pigs in vitro. Am Rev Respir Dis 1991; 144: 636-641.
101. 101. Crimi N, Polosa R, Pulvirenti G et al. Effect of an inhaled neutral endopeptidase inhibitor, phosphoramidon, on baseline airway calibre and bronchial responsiveness to bradykinin in asthma. Thorax 1995; 50: 505-510.
102. 102. Chatelain C, Pochon N, Lacroix JS. Functional effects of phosphoramidon and captopril on exogenous neuropeptides in human nasal mucosa. Eur Arch Otorhinolaryngol 1995; 252: 83-85.
103. 103. Ohkubo K, Okuda M, Kaliner MA. Immunological localization of neuropeptide-degrading enzymes in the nasal mucosa. Rhinology 1994; 32: 130-133.
104. 104. Abraham WM, Ahmed A, Cortes A et al. Airway effects of inhaled bradykinin, substance P and neurokinin A in sheep. J Allergy Clin Immunol 1991; 87: 557-564.
105. 105. Baraniuk JN, Lundgren JD, Okayama M et al. Substance P and neurokinin A in human nasal mucosa. Am J Respir Cell Mol Biol 1991; 4: 228-236.
106. 106. Braunstein G, Fajac I, Lacronique J, Frossard N. Clinical and inflammatory responses to exogenous tachykinins in allergic rhinitis. Am Rev Respir Dis 1991; 144: 630-635.
107. 107. Bertrand C, Geppetti P (1996): Tachykinin and kinin receptor antagonists: therapeutic perspectives in allergic airway disease. Trends Pharmacol Sci 1996; 17: 255-259.
108. 108. Sanderson CJ. Interleukin 5 and the regulation of eosinophil production. In: Smith H. Cook RM, eds Immunopharmacology of Eosinophils. London: Academic Press, 1993; 11-24
109. 109. Hogan SP, Foster PS. Cytokines as targets for the inhibition of eosinophillic inflammation. Pharmacol Ther 1997; 74: 259-283.
110. 110. Mauser PJ, Pitman A, Witt A et al. Inhibitory effect of the TRFK-5 anti-IL-5 antibody in a guinea pig model of asthma. Am Rev Respir Dis 1993; 148: 1623-1627.
111. 111. Boey H, Rosenbaum R, Castracane J, Borish L. Interleukin-4 is a neutrophil activator. J Allergy Clin Immunol 1989; 83: 978-984.
112. 112. Hellquist HB, Karlsson MG. Nasal memory T-lymphocytes capable of pruducing IL 4 in the allergic reaction. Allergy 1992; 47: 334-336.
113. 113. Bradding P, Feather IH, Wilson S et al. Immunolocalization of cytokines in the nasal mucosa of normal and perennial rhinitic subjects. The mast cell as a source of IL-4, IL-5 and IL-6 in human allergic mucosal inflammation. J Immunol 1993; 151: 3853-3865.
114. 114. Gosset P, Malaquin F, Delneste Y et al. Interleukin-6 and interleukin-1 alpha production is associated with antigen-induced late nasal response. J Allergy Clin Immunol 1993; 92: 878-890.
115. 115. Sim TC, Recce LM, Hilsmeier KA, Grant JA, Alam R. Secretion of chemokines and other cytokines in allergen-induced nasal responses: inhibition by topical steroid treatment. Am J Respir Crit Care Med 1995; 152: 927-933.
116. 116. Lantero S, Sacco O, Scala C, Morelli MC, Rossi GA. Eosinophil locomotion and the release of IL-3 and IL-5 by allergen-stimulated mononuclear cells are effectively downregulated in vitro by budesonide. Clin Exp Allergy 1996; 26: 656-664.
117. 117 Galli SJ, Gordon JR, Wershil BK et al. Mast cell and eosinophil cytokines in allergy and inflammation. In: Gleich GJ, Kay AB, eds. Eosinophils in Allergy and Inflammation. New York: Marcel Dekker, 1994; 255-280.
118. 118. Nonaka M, Nonaka R, Jordana M, Dolovich J. GM-CSF, IL-8, IL-1R, TNF-αR and HLA-DR in nasal epithelial cells in allergic rhinitis. Am J Resp Care Crit Med 1996; 153: 1674-1681.
119. 119. Calderon MA, Devalia JL, Prior AJ, Sapsford RJ, Davies RJ. A comparison of cytokine release from epithelial cells cultured from nasal biopsy specimens of atopic patients with and without rhinitis and nonatopic subjects without rhinitis. J Allergy Clin Immunol 1997; 99: 65-76.
120. 120. Durham SR, Ying S, Varney VA. Cytokine messenger RNA expression for IL-3, IL-4, IL-5, and granulocyte/macrophage-colony-stimulating factor in the nasal mucosa after local allergen provocation: relationship to tissue eosinophilia. J Immunol 1992; 148: 2390-2394.
121. 121. Altman LC, Ayars GH, Baker C, Luchtel DL. Cytokines and eosinophil-derived cationic proteins upregulate intracellular adhesion molecule-1 on human nasal epithelial cells. J Allergy Clin Immunol 1993; 92: 527-536.
122. 122. Wooley KL, Adekrith E, Woolley MJ, Ellis R, Jordana M, O'Byrne PM. Effects of allergen challenge on eosinophils, eosinophil cationic protein, and granulocyte-macrophage colony stimulating factor in mild asthma. Am J Respir Crit Care Med 1995; 151: 1915-1924.
123. 123 Ohnishi T, Kita H, Weiler D et al. IL-5 is the predominant eosinophil-active cytokine in the antigen-induced pulmonary late-phase reaction. Am Rev Respir Dis 1993; 147: 901-907.
124. 124. Kraneveld LD, Nijkamp FP, Van Oosterhout AJM. Role for neurokinin-2 receptor in interleukin-5-induced airway hyperresponsiveness but not eosinophilia in guinea pigs. Am J Respir Crit Care Med 1997; 156: 367-374.
125. 125. Selig W, Tocker J. Effect of interleukin-1 receptor antagonist on antigen-induced pulmonary responses in guinea pigs. Eur J Pharmacol 1992; 213: 331-336.
126. 126. Tsukagoshi H, Sun J, Kwon O, Barnes PJ, Chung KF. Role of neutral endopeptidase in bronchial hyperresponsiveness to bradykinin induced by IL-1β. J Appl Physiol 1995; 78: 921-927.
127. 127. Tsukagoshi II, Robbins RA, Barnes PJ, Chung KF. Role of nitric oxide and superoxide anions in interleukin-1β-induced airway hyperresponsiveness to bradykinin. Am J Respir Crit Care Med 1994; 150: 1019-1025.
128. 128. Barnes PJ, Chung KF, Page CP. Inflammatory mediators of asthma: an update. Pharmacol Rev 1998; 50: 515-596.
129. 129. Rajakulasingam K, Hamid Q, O'Brien F et al. RANTES in human alllergen-induced rhinitis: cellular source and relation to tissue eosinophilia. Am J Respir Crit Care Med 1997; 155: 696-703.
130. 130. Minshall EM, Cameron L, Lavigne F et al. Eotaxin mRNA and protein expression in chronic sinusitis and allergen-induced nasal responses in seasonal allergic rhinitis. Am J Respir Cell Mol Biol 1997; 17: 683-690.
131. 131. Gosset P, Tillie-Leblond L, Malaquin F, Durieu J, Wallaert B, Tonnel AB. Interleukin 8 secretion in patients with allergic rhinitis after an allergen challenge: interleukin-8 is not the main chemotactic factor present in nasal lavage. Clin Exp Allergy 1997; 27: 379-388.
132. 132. Meltzer EO. The pharmacological basis for the treatment of perennial allergic rhinitis and non-allergic rhinitis with topical corticosteroids. Allergy 1997; 52 (36 Suppl): 33-40.
133. 133. Kuna P, Alam R, Ruta U, Gorski P. RANTES induces nasal mucosal inflammation rich in eosinophils, hasophils and lymphocytes in vivo. Am J Respir Crit Care Med 1998; 157: 873-879.
134. 134. Garrelds IM, Van Amsterdam JGC, De Graaf-in't Veld C, Gerth van Wijk R. Nitric oxide metabolites in nasal lavage fluid of patients with house dust mite allergy. Thorax 1995; 50: 275-279.
135. 135. Martin U, Bryden K, Devoy M, Howarth P. Increased levels of exhaled nitric oxide during nasal and oral breathing in subjects with seasonal rhinitis. J Allergy Clin Immunol 1996; 97: 768-772.
136. 136. Kharitonov SA, Rajakulasingam K, O'Connor B, Durham SR, Barnes PJ. Nasal nitric oxide is increased in patients with asthma and allergic rhinitis and may be modulated by nasal glycocorticoids. J Allergy Clin Immunol 1997; 99: 58-64
137. 137. Barnes PJ, Liew FY. Nitric oxide and asthmatic inflammation. Immunology Today 1995; 16: 128-130.
138. 138. Turner PJ, Maggs JRL, Foreman JC. Inhibitors of nitric oxide synthase induce hyperresponsiveness in the human nasal airway. Allergologie 1998; 11: 559.
139. 139. Ricciardolo FL, Geppetti P, Mistretta A et al. Randomised double blind placebo-controlled study of the effect of inhibition of nitric oxide synthesis in bradykinin-induced asthma Lancet 1996; 348: 374-377.
140. 140. Nijkamp FP, Van der Linde HJ, Folkerts G. Nitric oxide synthesis inhibitors induce airway hyperresponsiveness in the guinea pig in vivo and in vitro - role of the epithelium. Am Rev Resp Dis 1993; 148: 727-734.
141. 141. Eiserich JP, Hristova M, Cross CE et al. Formation of nitric oxide-derived inflammatory oxidants by myeloperoxidase in neutrophils. Nature 1998; 391: 393-397.
142. 142. Lurie A, Nadel JA, Roismann G et al. Role of neutral endopeptidase and kininase II on substance-P induced increase in nasal obstruction in patients with allergic rhinitis Am J Respir Crit Care Med 1994; 149: 113-117.
143. 143. Farmer SG, Wilkins DE, Meeker SA, Seeds EAM, Page CP. Effects of bradykinin receptor antagonists on antigen-induced respiratory distress, airway hyperresponsiveness and eosinophilia in guinea pigs. Br J Pharmacol 1992; 107: 653-659.
144. 144. Soler M, Sielczak M, Abraham WM. A bradykinin-antagonist blocks antigen-induced airway hyperresponsiveness and inflammation in sheep. Pulm Pharmacol 1990; 3: 9-15.
145. 145. Venge P, Dahl R, Hallgren R. Enhancement of factor XII reactions by eosinophil cationic protein. Thromb Res 1979; 14: 641-649.
146. 146. Reddigari SR, Silverberg M, Kaplan AP. Bradykinin formation in allergic diseases and hereditary angiodema. In: Farmer SJ, ed. The Kinin System. London: Academic Press, 1997; 265-285.
147. 147. Baumgarten CR, Nichols RC, Naclerio RM, Proud D. Concentrations of glandular kallikreln in human nasal secretions increase during experimentally induced allergic rhinitis. J Immunol 1986; 137: 1323-1328.
148. 148 Gustafson EJ, Schmaler AH, Wachtfogel YT, Kaufman N, Kucich U, Colman RW. Human neutrophils contain and bind high molecular weight kininogen. J Clin Invest 1989; 84: 28-35.
149. 149. Henderson LM, Figueroa CD, Muller-Esterl W, Bhoola KD. Assembly of contact-phase factors on the surface of the human neutrophil membrane. Blood 1994; 84: 474-482.
150. 150. Omini C, Burnelli G, Hernandez A, Daffonchio L. Bradykinin and substance P potentiate acetylcholine-induced bronchoconstriction in the guinea pig. Eur J Pharmacol 1989; 163: 195-197.
151. 151. Fox AJ, Lalloo UG, Belvisi MG, Bernareggi M, Fan Chung K, Barnes PJ. Bradykinin-evoked sensitisation of airway sensory nerves: a mechanism for ACE-inhibitor cough. Nature Med 1996; 2: 814-817.
152. 152. Geppetti P, Tramontana M, Santicioli P, Del-Bianco E, Giuliani S, Maggi CA. Bradykinin-induced release of calcitonin gene-related peptide from capsaicin-sensitive nerves in guinea-pig atria: mechanism of action and calcium requirements. Neuroscience 1990; 38: 687-692.
153. 153. Ferreira SH, Lorenzetti BB, Poole S. Bradykinin initiates cytokine-mediated inflammatory hyperalgesia. Br J Pharmacol 1993; 110: 1227-1231.
154. 154. Tiffany CW, Burch RM. Bradykinin stimulates tumour necrosis factor and interleukin-1 release from macrophages. FEBS Lett 1989; 247: 189-192.
155. 155. Evans DM, Jones DM, Pitt GR et al. Synthetic inhibitors of human tissue kallikrein. Immunopharmacology 1996; 32: 117-118.
156. 156. Spina D, McKenniff MG, Coyle AJ et at. Effect of capsaicin on PAF-induced bronchial hyperresponsiveness and pulmonary cell accumulation in the rabbit. Br J Pharmacol 1991; 103: 1268-1274.
157. 157. Seeds EA, Coyle AJ, Page CP. The effect of the selective PAF antagonist WEB 2170 on PAF and antigen-induced airway hyperresponsiveness and eosinophil infiltration. J Lipid Mediators 1991; 4: 111-121.
158. 158. Costa JJ, Weller PF, Galli SJ. The cells of the allergic response. J Am Med Assoc 1997; 278: 1815-1822.
159. 159. Bachert C, Behrendt H, Kosbusch K, Hauser U, Ganzer U. Possible role of macrophages in allergic rhinitis. Int Arch Allergy Appl Immunol 1991; 94: 244-245.
160. 160. Sur S, Glitz DG, Kita H et al. Localization of eosinophil-derived neurotoxin and eosinophil cationic protein in neutrophilic leukotytes. J Leukocyte Biol 1998; 63: 715-722.
161. 161. Texeira MM, Williams TJ, Hellewell PG. Mechanisms and pharmacological manipulation of eosinophil accumulation in vivo. Trends Pharmacol Sci 1995; 16: 418-423.
162. 162. Abraham WM, Ahmed A, Sielczak MW, Narita M, Arrhenius T, Elices MJ. Blockade of late-phase airway responses and airway hyperresponsiveness in allergic sheep with a small-molecule peptide inhibitor of VLA-4. Am J Respir Crit Care Med 1997; 156: 696-703.
163. 163. Laberge S, Rabb H, Issekutz TB, Martin JG. Role of VLA-4 and LFA-1 in allergen-induced airway hyperresponsiveness and lung inflammation in the rat. Am J Respir Crit Care Med 1995; 151: 822-829.
164. 164. Kraneveld AD, van Ark I, Van Der Linde HJ, Fattah D, Nijkamp FP, Van Oosterhout AJ. Antibody to very late activation antigen 4 prevents interleukin-5-induced airway hyperresponsiveness and eosinophil infiltration in the airways of guinea pigs. J Allergy Clin Immunol 1997; 100: 242-250.
165. 165 Abraham WM, Sielczak MW, Ahmed A et al. Alpha 4-integrins mediate antigen-induced late bronchial responses and prolonged airway hyperresponsiveness in sheep. J Clin Invest 1994; 93: 776-787.